📊 The Science of Microdosing
Evidence-based visual guide to psilocybin research
🔬 The Science of Microdosing
What Research Tells Us About Sub-Perceptual Psilocybin
Psilocybin (2015-2024)
Psychedelic Research
Psychedelic Medicine
💊 What is Microdosing?
Sub-perceptual doses taken on a regular schedule
Typical Dose Range
Dried Psilocybe cubensis
Common Protocols
With regular rest days
Typical Duration
Followed by break periods
Goal
Sub-threshold effects only
🧠 Effects on the Brain
How psilocybin interacts with neural systems
Increased Neural Connectivity
Psilocybin promotes communication between brain regions that don't normally interact, potentially enabling new thought patterns.
Enhanced Neuroplasticity
Studies show increased dendritic spine density and BDNF expression, supporting brain adaptability and learning.
Default Mode Network Modulation
Reduced DMN activity is associated with decreased rumination and ego dissolution, potentially beneficial for depression.
5-HT2A Receptor Agonism
Primary mechanism of action - binding to serotonin receptors triggers downstream effects on mood and cognition.
⚙️ Mechanism of Action
How psilocybin works in the body
Ingestion
Psilocybin is consumed orally
Conversion
Liver converts psilocybin to psilocin
Binding
Psilocin binds to 5-HT2A serotonin receptors
Effects
Altered perception, mood, and cognition
📈 Reported Benefits in Studies
Self-reported outcomes from survey research
Improved Mood
Enhanced Creativity
Reduced Anxiety
Better Focus
Increased Energy
Social Connectedness
📚 Data Sources
📐 Evidence Quality Pyramid
Understanding the strength of current research
Limited - emerging
Growing - several completed
Moderate evidence
Extensive data
Abundant
Current State of Evidence: While anecdotal reports and surveys are abundant, rigorous double-blind placebo-controlled trials are still emerging. Early RCTs show mixed results, with some studies finding significant effects and others suggesting placebo may account for benefits. More research is needed.
⚖️ Microdose vs. Full Dose
Key differences in dosing approaches
| Factor | Microdose (0.1-0.3g) | Full Dose (3-5g) |
|---|---|---|
| Duration | 4-6 hours (subtle) | 4-8 hours (intense) |
| Visual Effects | None | Significant |
| Functionality | Normal daily activities | No activities possible |
| Preparation Needed | Minimal | Extensive (set, setting, sitter) |
| Psychological Risk | ||
| Therapeutic Potential | ||
| Mystical Experience | Rare/None | Common (with proper dose) |
📅 Research Timeline
Key milestones in psilocybin science
Johns Hopkins Landmark Study
First rigorous study showing psilocybin can occasion mystical experiences with lasting positive effects.
Depression & Anxiety Trials
NYU and Johns Hopkins publish landmark studies on psilocybin for cancer-related distress.
First Systematic Microdosing Studies
Polito & Stevenson publish first detailed longitudinal study of microdosing effects.
First Controlled Microdosing RCTs
Imperial College London publishes first double-blind placebo-controlled microdosing study.
Ongoing Research
Multiple Phase 2 and 3 trials underway. FDA Breakthrough Therapy designation for treatment-resistant depression.
⚠️ Important Considerations
What the science also tells us
Placebo Question
Some RCTs suggest expectation effects may account for significant portion of benefits. Blinding is difficult.
Individual Variation
Responses vary widely. What works for one person may not work for another. Optimal dose differs.
Cardiac Concerns
Chronic 5-HT2B activation may affect heart valves. Long-term safety data is limited.
Drug Interactions
Contraindicated with SSRIs, MAOIs, lithium. Medical screening essential.
⚖️ Legal Disclaimer
Psilocybin remains a Schedule I controlled substance in most jurisdictions. This information is for educational purposes only and does not constitute medical advice. The legal status varies by location - research is conducted under specific regulatory frameworks. Always consult with healthcare providers and verify local laws.